Genocury’s In Vivo CAR-T JY231 Shows Early Promise in Refractory Neurologic Autoimmune Diseases
A Chinese research team has reported encouraging early clinical results for JY231, an investigational lentiviral in vivo CD19 CAR-T therapy that generates therapeutic CAR-T cells directly inside the patient’s body, potentially eliminating two of…